Amgen Stock News

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Associatio

THOUSAND OAKS, Calif., March 10, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will virtually present at the 32nd Annual Oppenheimer Healthcare Conference at 11:20 a.m.

Which pharmaceutical companies can rocket your portfolio right now? Let's take a look.

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Late-Breaking Oral Presentation Includes Two-Year Follow-Up Data from CodeBreaK 100 Study – the Most Advanced KRAS G12C Clinical Dataset Pre-Clinical Data Evaluating Half-Life Extended BiTE® Molecule AMG 794 Targeting CLDN6 to be Presented for the First Time Amgen announced that new data from across its oncology portfolio and pipeline will be presented at the American […] The post Amgen to Present Long-Term Outcomes for Lumakras (Sotorasib) In KRAS G12C-Mutated NSCLC at Aacr 2022 appeared first on AiThority .

Amgen, Inc. (AMGN) Management Presents at 42nd Annual Cowen Healthcare Conference (Transcript)

Amgen (AMGN) is the featured stock from February's Dividend Growth Stocks Model Portfolio.

These three stocks are solid value picks in different areas of healthcare.

Week 10 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge

Amgen (AMGN) signed an agreement with U.K.''s National Health Service for its lung cancer drug Lumykras (sotorasib).The NHS noted that following a confidential discount deal the drug…

Major companies in the biologics market include AbbVie, Johnson & Johnson, Amgen, Sanofi S. A, F. Hoffmann-La Roche Ltd. , GlaxosmithKline, Novartis AG, Pfizer Inc. , Teva Pharmaceuticals and CSL. Major companies in the biologics market include AbbVie, Johnson & Johnson, Amgen, Sanofi S. A, F. Hoffmann-La Roche Ltd. , GlaxosmithKline, Novartis AG, Pfizer Inc. , Teva Pharmaceuticals and CSL.

Amgen Inc. (NASDAQ:AMGN) is an American multinational biopharmaceutical company.

Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. , Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. , Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co.

Ten new stocks enter the BofA quantmental Alpha Surprise Model portfolio for March, while 14 stocks drop out.